Gland Pharma gets USFDA’s approval for Phytonadione Injectable Emulsion

12 Dec 2024 Evaluate

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vitamin K1 Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc. 

This Product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity. The company is eyeing to launch this Product through its marketing partners in the near future. According to IQVIA, the product had US sales of around $15 million for the twelve months ending September 2024.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.


Gland Pharma Share Price

1524.25 3.85 (0.25%)
21-Feb-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1643.05
Dr. Reddys Lab 1151.95
Cipla 1474.30
Lupin 1906.15
Zydus Lifesciences 885.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on